According to the staff of the US Federal Trade Commission, legislation pending before the State of Minnesota legislature that seeks to exempt certain activities by state health care cooperatives from federal and state antitrust law would likely raise health care costs and reduce insurance coverage for consumers there. The FTC's Bureau of Competition, Bureau of Economics and Office of Policy Planning filed a detailed comment with Minnesota State Representative Tom Emmer (Republican), responding to his request for the FTC's views on Minnesota House Bill HF No 120 and its companion legislation, Senate Bill SF No 203.
The FTC staff comment observes that the bills appear to authorize anticompetitive activities, including price fixing and concerted refusals by the cooperatives and their members to deal with health plans and other purchasers. According to the comment, "nothing in the bills is likely to prevent the harmful effects that arise from immunizing price fixing...[and] these bills would deprive health care consumers of the protections of the antitrust laws and the benefits of competition."
Specifically, the comment states that "the bills, if enacted, would harm Minnesota consumers through higher prices for health care services, higher insurance premiums, lower levels of insurance coverage, and lower wages. All Minnesota taxpayers, moreover, would likely bear the burden of this proposal, as state-sponsored insurance programs would have to pay more to provide coverage for the most vulnerable segments of the population." The comment also explained that an antitrust exemption is unnecessary to improve health care quality and that the bills may not succeed in immunizing "health care cooperatives from liability for conduct that violates federal law."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze